Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 6711.5 | 66 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 18450.0 | 59 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 20020.0 | 70 | |
N2759 | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 21408.0 | 53 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 12603.0 | 56 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 16614.0 | 61 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 13878.0 | 59 | |
N2586 | Poly(I:C) | 2 | ug/mL | 3 | RANTES | 12673.0 | 52 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 25.5 | 56 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 134.0 | 69 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 33.0 | 65 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 189.0 | 67 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 33.0 | 64 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 541.5 | 58 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 31.0 | 70 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 195.0 | 66 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 7821.5 | 74 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 10375.0 | 59 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 6890.0 | 60 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 7132.0 | 69 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 9197.0 | 55 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 12036.0 | 55 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 7884.0 | 57 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | RANTES | 8381.0 | 71 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | RANTES | 613.0 | 59 |